- Home
- All Stock List
- BSE
- Sanofi Consumer Healthcare India Ltd Share Price
Sanofi Consumer Healthcare India Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap
4,946.60
53.95 (1.10%)
-
Underperforms Index
0%
Return (1Y)
Underperformed BSE Healthcare by 14.57%
-
More Volatile
1.34%
Standard Deviation (1Y)
Higher than BSE Healthcare by 0.28%
-
Not so consistent
5/8
Months
underperformed BSE Healthcare
-
AxisDirect View
No View
5,499
4,360
News & Announcements
-
Sanofi Consumer Healthcare India revises record date for final dividend
09 - Apr - 2025 12:00 | 5 days ago
Sanofi Consumer Healthcare India has revised the record date from 28 April 2025 to 17 April 2025 for final dividend of Rs 55 per equity share of face value of Rs 10 each for the year ended 31 December 2024.
Powered by Capital Market - Live News
-
According to an exchange filing, Mistry has decided to resign to explore new opportunities outside the organization.
In addition, Rupendra Sachdev, the head of commercial operations and a senior management personnel, has also decided to step down from his current role.
His resignation will be effective from the end of business hours on 30 April 2025, marking his last working day with the company. Sachdev is leaving to pursue his entrepreneurial aspirations.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.
The counter shed 0.85% to Rs 4,740.15 on the BSE.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India AGM scheduled
19 days ago
-
According to an exchange filing, Mistry has decided to resign to explore new opportunities outside the organization.
In addition, Rupendra Sachdev, the head of commercial operations and a senior management personnel, has also decided to step down from his current role.
His resignation will be effective from the end of business hours on 30 April 2025, marking his last working day with the company. Sachdev is leaving to pursue his entrepreneurial aspirations.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.
The counter shed 0.85% to Rs 4,740.15 on the BSE.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India AGM scheduled
19 days ago
-
Sanofi Consumer posts PAT of Rs 46 crore in Q3
52 days ago
Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY).
Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India revises record date for final dividend
09 - Apr - 2025 12:00 | 5 days ago
Sanofi Consumer Healthcare India has revised the record date from 28 April 2025 to 17 April 2025 for final dividend of Rs 55 per equity share of face value of Rs 10 each for the year ended 31 December 2024.
Powered by Capital Market - Live News
-
According to an exchange filing, Mistry has decided to resign to explore new opportunities outside the organization.
In addition, Rupendra Sachdev, the head of commercial operations and a senior management personnel, has also decided to step down from his current role.
His resignation will be effective from the end of business hours on 30 April 2025, marking his last working day with the company. Sachdev is leaving to pursue his entrepreneurial aspirations.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.
The counter shed 0.85% to Rs 4,740.15 on the BSE.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India AGM scheduled
19 days ago
-
Sanofi Consumer posts PAT of Rs 46 crore in Q3
52 days ago
Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY).
Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India revises record date for final dividend
09 - Apr - 2025 12:00 | 5 days ago
Sanofi Consumer Healthcare India has revised the record date from 28 April 2025 to 17 April 2025 for final dividend of Rs 55 per equity share of face value of Rs 10 each for the year ended 31 December 2024.
Powered by Capital Market - Live News
-
According to an exchange filing, Mistry has decided to resign to explore new opportunities outside the organization.
In addition, Rupendra Sachdev, the head of commercial operations and a senior management personnel, has also decided to step down from his current role.
His resignation will be effective from the end of business hours on 30 April 2025, marking his last working day with the company. Sachdev is leaving to pursue his entrepreneurial aspirations.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.
The counter shed 0.85% to Rs 4,740.15 on the BSE.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India AGM scheduled
19 days ago
-
According to an exchange filing, Mistry has decided to resign to explore new opportunities outside the organization.
In addition, Rupendra Sachdev, the head of commercial operations and a senior management personnel, has also decided to step down from his current role.
His resignation will be effective from the end of business hours on 30 April 2025, marking his last working day with the company. Sachdev is leaving to pursue his entrepreneurial aspirations.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.
The counter shed 0.85% to Rs 4,740.15 on the BSE.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India AGM scheduled
19 days ago
-
Sanofi Consumer posts PAT of Rs 46 crore in Q3
52 days ago
Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY).
Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE.
Powered by Capital Market - Live News
Stock Trivia
FII shareholding in Sanofi Consumer Healthcare India Ltd has decreased by -9.37% since past 3 Months
Sanofi Consumer Healthcare India Ltd has the highest P/B ratio according to FY 202412 data among stocks in Pharmaceuticals Sector
FII shareholding in Sanofi Consumer Healthcare India Ltd has decreased by -9.37% since past 3 Months
MF shareholding in Sanofi Consumer Healthcare India Ltd has increased by 9.34% since past 3 Months
Sanofi Consumer Healthcare India Ltd has the highest P/B ratio according to FY 202412 data among stocks in Pharmaceuticals Sector
FII shareholding in Sanofi Consumer Healthcare India Ltd has decreased by -9.37% since past 3 Months
Sanofi Consumer Healthcare India Ltd has the highest P/B ratio according to FY 202412 data among stocks in Pharmaceuticals Sector
